Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Thresholds For Therapies: Highlights Of The St Gallen International Expert Consensus On The Primary Therapy Of Early Breast Cancer 2009

A. Goldhirsch, J. Ingle, R. Gelber, A. Coates, B. Thuerlimann, H. Senn
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The 11th St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers. Any positive level of estrogen receptor (ER) expression is considered sufficient to justify the use of endocrine adjuvant therapy in almost all patients. Overexpression or amplification of HER2 by standard criteria is an indication for anti-HER2 therapy for all but the very lowest risk invasive tumours. The corollary is that ER and HER2 must be reliably and accurately measured. Indications for cytotoxic adjuvant therapy were refined, acknowledging the role of risk factors with the caveat that risk per se is not a target. Proliferation markers, including those identified in multigene array analyses, were recognised as important in this regard. The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm.
This paper references
cancer in postmenopausal women with osteoporosis
T Powles (2009)
10.1158/0008-5472.SABCS-13
BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.
H. Mouridsen (2009)
Axillary sentinel lymph node: how low can you go? Breast
V. Galimberti (2009)
10.1056/NEJMOA021967
A gene-expression signature as a predictor of survival in breast cancer.
M. J. van de Vijver (2002)
10.1016/S0960-9776(09)70270-X
The biological information obtainable from circulating tumor cells.
M. Cristofanilli (2009)
10.1016/j.ijrobp.2009.02.031
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO).
B. Smith (2009)
Adjuvant therapy of triple negative
EA Perez
Pharmacogenetics to drive breast cancer treatments. The Breast
HL McLeod (2009)
The changes.
A. Cole (1991)
Targeting HER 2 in the adjuvant setting : dealing with new standards and open questions
IE Smith (2009)
10.1016/j.breast.2008.09.001
Relationship between body mass index, waist circumference and waist to hip ratio and the steroid hormone receptor status in breast carcinoma of pre- and postmenopausal women.
Rosilene de Lima Pinheiro (2009)
: getting to treat the core
MS Wicha
10.1093/ANNONC/MDM271
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
A. Goldhirsch (2007)
10.1210/er.2006-0045
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
G. Arpino (2008)
Axillary sentinel lymph node : how low can you go ?
V Galimberti (2009)
10.1073/pnas.0806092105
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
S. Rottenberg (2008)
10.1200/JCO.2008.19.5594
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes.
B. Šeruga (2009)
Clinical relevance of HER-2 overexpression/amplification in patients with small tumor size (pT1a-b) and node-negative breast cancer
G Curigliano (2009)
10.1016/S0960-9776(09)70033-5
S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer
L. Gianni (2009)
10.1016/S0960-9776(09)70291-7
Targeting HER2 in the adjuvant setting: dealing with new standards and with open questions.
I. Smith (2009)
Modulation of angiogenesis : clinical impact ( in
RS Kerbel
10.1016/S0960-9776(09)70026-8
S18 Pharmacogenetics to drive breast cancer treatments
H. McLeod (2009)
10.1016/S0960-9776(09)70287-5
Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?
D. Hayes (2009)
10.1016/S0960-9776(09)70049-9
S41 Targeting HER2 in the adjuvant setting: Dealing with new standards and open questions
I. Smith (2009)
Pharmacogenetics to drive breast cancer treatments. The Breast
HL McLeod (2009)
10.1016/S0960-9776(09)70045-1
S37 Is there a standard type and duration of adjuvant chemotherapy
D. Hayes (2009)
Gene expression and benefit of chemotherapy in women with nodenegative , estrogen receptorpositive breast cancer
S Paik (2006)
10.1158/0008-5472.CAN-05-4414
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.
A. V. Ivshina (2006)
10.1007/s10549-010-0736-z
Adjuvant therapy of triple negative breast cancer
E. Perez (2010)
10.1056/NEJMOA053028
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
H. Joensuu (2006)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
N. Williams (2007)
10.1200/JCO.2007.15.8659
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
S. Chia (2008)
10.1016/S0960-9776(09)70048-7
S40 Should genomic profiles be used to determine who should receive adjuvant chemotherapy
K. Albain (2009)
FoxA 1 translates epigenetic signatures into enhancerdriven lineagespecific transcription
M Lupien (2008)
10.1038/nature03445
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H. Farmer (2005)
10.1016/j.breast.2008.11.001
Pharyngo-laryngeal discomfort after breast surgery: comparison between orotracheal intubation and laryngeal mask.
M. Parotto (2009)
10.1200/JCO.2008.17.0829
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
G. Viale (2008)
Combined ER and HER-targeted therapy in breast cancer treatment
K Osborne (2009)
College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
A Wolff (2007)
10.1158/0008-5472.SABCS-79
Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy.
G. Minckwitz (2009)
10.1016/j.cell.2008.01.018
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
M. Lupien (2008)
10.1016/S0960-9776(09)70025-6
S17 Breast cancer stem cells: Getting to treat the core
M. Wicha (2009)
Adjuvant therapies for premenopausal women with endocrineresponsive disease
NE Davidson (2009)
10.1093/ANNONC/MDI326
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
A. Goldhirsch (2005)
Annals of Oncology special article
(2009)
Clinical relevance of HER-2 overexpression/amplification in patients with small tumor size (pT1a-b) and node-negative breast cancer
G Curigliano (2009)
10.1016/S0960-9776(09)70020-7
S12 Five year results of a randomised placebo controlled trial of lasofoxifene (PEARL) on the incidence of ER positive breast cancer in postmenopausal women with osteoporosis
T. Powles (2009)
Five year results of a randomised placebo controlled trial of lasofoxifene (PEARL) on the incidence of ER positive breast cancer in postmenopausal women with osteoporosis
T Powles (2009)
10.1016/j.ccr.2009.02.007
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
S. Loges (2009)
10.1002/bjs.5209
Meta‐analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer
Y. Xing (2006)
Estrogen signalling through the transmembrane G protein - coupled receptor GPR 30
ER Prossnitz (2009)
10.1158/1078-0432.CCR-08-0974
Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
M. Dowsett (2008)
An Autocrine VEGF / VEGFR 2 and p 38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells
Reidun Aesoy (2008)
10.1200/JCO.2007.14.2646
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.
J. Baselga (2009)
Adjuvant therapy of triple negative
EA Perez
A geneexpression signature as a predictor of survival in breast cancer
MJ vandeVijver (2002)
10.1038/ncponc0591
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
J. Bogaerts (2006)
Combined ER and HER-targeted therapy in breast cancer treatment
K Osborne (2009)
10.1007/s10549-008-9912-9
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
B. Thürlimann (2008)
10.1038/nature06487
Endogenous human microRNAs that suppress breast cancer metastasis
S. Tavazoie (2008)
10.1200/JCO.2005.04.7985
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
S. Paik (2006)
10.1038/NCHEMBIO775
Virtual and biomolecular screening converge on a selective agonist for GPR30
C. Bologa (2006)
10.1016/j.ccr.2009.01.021
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
J. Ebos (2009)
10.1056/NEJMOA052122
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
10.1038/231541a0
Cancer Treatment
F. Roe (1971)
10.1016/S0960-9776(09)70043-8
S35 Adjuvant therapies for premenopausal women with endocrine-responsive disease
N. Davidson (2009)
10.1016/S1470-2045(10)70257-6
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
J. Cuzick (2010)
Clinical relevance of HER - 2 overexpression / amplification in patients with small tumor size ( pT 1 a - b ) and nodenegative breast cancer
G Curigliano (2009)
10.1093/ANNONC/MDM509
Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.
M. Colleoni (2008)
10.1200/JCO.2008.17.5182
Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ.
C. Dunne (2009)
10.1016/j.breast.2008.09.002
Immuno-modulatory effects of relaxation training and guided imagery in women with locally advanced breast cancer undergoing multimodality therapy: a randomised controlled trial.
O. Eremin (2009)
10.1158/0008-5472.CAN-08-2741
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.
E. Charafe-Jauffret (2009)
10.1200/JCO.2007.14.4147
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
C. Liedtke (2008)
Annals of Oncology special article
(2009)
Axillary sentinel lymph node: how low can you go? Breast
V. Galimberti (2009)
10.1016/S0960-9776(09)70036-0
S28 Breast conservation and clear margins: Invasive or in situ involvement
M. Morrow (2009)
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of nodenegative breast cancers
S Chia (2008)
10.1016/S0960-9776(09)70051-7
S43 Review of new targeted drugs: Crawling towards the adjuvant setting
J. Baselga (2009)
10.1016/S0960-9776(09)70269-3
Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment.
G. Viale (2009)
10.1093/ANNONC/MDJ095
Survival and prognostic factors in BRCA1-associated breast cancer.
C. Brekelmans (2006)
Axillary sentinel lymph node : how low can you go ?
TM Tuttle (2009)
College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
A Wolff (2007)
10.1016/S0960-9776(09)70032-3
S24 Update of the FINHER trial based on 5 years of follow-up
H. Joensuu (2009)
10.1210/me.2008-0100
Unique ERalpha cistromes control cell type-specific gene regulation.
S. Krum (2008)
Modulation of angiogenesis : clinical impact ( in
RS Kerbel
10.1245/s10434-008-9960-8
Presence of Lobular Carcinoma In Situ Does Not Increase Local Recurrence in Patients Treated with Breast-Conserving Therapy
R. Ciocca (2008)
10.1016/S0960-9776(09)70047-5
S39 Treatment of postmenopausal women with hormone responsive breast cancer
E. Winer (2009)
Update of the HERA trial and the role of 1 year trastuzumab as adjuvant therapy for breast cancer
L Gianni (2009)
10.1016/j.breast.2008.09.004
Serum levels of angiogenic factors in early breast cancer remain close to normal.
D. Duranyildiz (2009)
10.1016/S0960-9776(09)70014-1
S6 Mining the steroid receptor cistrome for novel targets, biomarkers and risk alleles
M. Brown (2009)
10.1186/bcr2124
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
P. Wirapati (2008)
10.1146/annurev.physiol.70.113006.100518
Estrogen signaling through the transmembrane G protein-coupled receptor GPR30.
E. Prossnitz (2008)
10.1016/S0960-9776(09)70011-6
S3 The changes in breast cancer incidence: A result of recent changes in hormone use by postmenopausal women?
P. Ravdin (2009)
Survival and prognostic factors in BRCA 1associated breast cancer
CT Brekelmans (2006)
10.1158/1541-7786.MCR-07-2172
An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells
Reidun Aesoy (2008)
Combined ER and HERtargeted therapy in breast cancer treatment
K Osborne (2008)
Is there a standard type and duration of adjuvant chemotherapy? Breast
D. Hayes (2009)
cancer relapse
H Joensuu (2009)
10.1016/S0960-9776(09)70277-2
The follow-up of women at high risk for breast cancer relapse.
I. Smith (2009)
10.1158/1078-0432.CCR-07-4758
Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer
M. Ignatiadis (2008)
10.1016/S0960-9776(09)70023-2
S15 The (last?) word about biomarkers for angiogenesis
F. Bertolini (2009)
10.1016/j.radonc.2008.04.014
High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c.
M. Kyndi (2009)
Gene-expression signatures in breast cancer.
P. Helmbold (2003)
10.1186/1471-2407-7-178
Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy
U. Kraus-Tiefenbacher (2007)
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Lin Li (2009)
10.1111/j.1365-2559.2006.02402.x
Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index
P. Jalava (2006)
10.1200/JCO.2006.09.2775
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
A. Wolff (2007)
10.1056/NEJMoa0807684
Breast cancer after use of estrogen plus progestin in postmenopausal women.
R. Chlebowski (2009)
10.1016/S0140-6736(05)67887-7
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
M. Clarke (2005)
10.1016/j.ccr.2009.01.027
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Marta Páez-Ribes (2009)
10.2307/j.ctvzgb86t.9
Cancer
Zachary Hall (1906)
10.3816/CBC.2006.N.051
TAILORx: trial assigning individualized options for treatment (Rx).
J. Sparano (2006)
10.1038/nrm1962
EGF–ERBB signalling: towards the systems level
A. Citri (2006)
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists
JF Forbes (2008)
10.1016/S0960-9776(09)70276-0
Molecular imaging of breast cancer.
T. Oude Munnink (2009)
cancer relapse
H Joensuu (2009)
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists
JF Forbes (2008)
Accelerated partial breast irradiation consensus statement from the American Society of Therapeutic Radiology and Oncology
BD Smith (2009)
cancer in postmenopausal women with osteoporosis
T Powles (2009)
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
J. (2002)
10.1016/S0960-9776(09)70037-2
S29 Axillary sentinel lymph node: How low can you go?
V. Galimberti (2009)
10.1158/0008-5472.SABCS-09-62
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
D. Slamon (2009)
10.1016/S0960-9776(09)70281-4
Breast conservation and sentinel lymph node biopsy after neoadjuvant systemic therapy.
P. Veronesi (2009)
10.1200/JCO.2008.17.4789
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
S. Dellapasqua (2008)
10.1016/S0960-9776(09)70017-7
S9 Current knowledge on genetic predispositions for breast cancer
L. Brody (2009)
Axillary sentinel lymph node : how low can you go ?
TM Tuttle (2009)
10.1309/2YXRLEQVPPNRWHGA
Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory.
M. Ibrahim (2008)
Update of the FINHER trial based on 5 years of follow - up
H Joensuu (2009)
10.1056/NEJMOA052306
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart (2005)
10.2174/138161208786404362
PET imaging of steroid receptor expression in breast and prostate cancer.
G. Hospers (2008)
Is there a standard type and duration of adjuvant chemotherapy? Breast
D. Hayes (2009)
10.1016/S0960-9776(09)70082-7
0033 Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women by baseline estradiol levels
T. Powles (2009)
10.1200/JCO.2008.20.1681
Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ.
T. Tuttle (2009)
10.1007/S11912-009-0008-4
What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?
M. Higgins (2009)
10.1016/S0960-9776(09)70022-0
S14 Modulation of angiogenesis: Clinical impact (in breast cancer)
R. Kerbel (2009)
10.1016/j.ijrobp.2007.11.029
Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up.
B. Kreike (2008)
10.1186/bcr2208
Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis
J. Lewis-Wambi (2008)
10.1038/sj.clpt.6100343
Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen
N. Ntukidem (2008)



This paper is referenced by
The peripheral lymphocyte subsets correlates with clinicopathological characteristics of breast cancer patients
Yueting Han (2016)
A miR-26 a / E 2 F 7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer
J. Liu (2018)
Autoimmune responses to thyroid/breast shared antigens to develop novel and specific therapies and diagnostics
I. Muller (2016)
10.1111/jpi.12032
Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma
K. Jablonska (2013)
10.1371/journal.pone.0055901
Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma
F. Reyal (2013)
10.1093/carcin/bgr028
Breast cancer stem cells: treatment resistance and therapeutic opportunities.
F. Al-Ejeh (2011)
10.1586/era.09.177
From tumor size and HER2 status to systems oncology for very early breast cancer treatment
D. Roukos (2010)
10.5301/tj.5000624
Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast
Y. Xu (2018)
10.1111/j.1365-2559.2010.03716.x
Suitability of infiltrative lobular breast carcinoma for anti‐human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting
M. Vergine (2010)
10.1186/1471-2407-12-472
Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment
P. O. Dialla (2012)
10.1016/j.breast.2010.03.026
Management of triple negative breast cancer.
C. Oakman (2010)
10.2146/ajhp100492
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
S. Glueck (2011)
10.1016/j.ejso.2011.04.014
Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience.
R. G. Kim (2011)
Androgen receptor phosphorylation in prostate diseases
Jennifer M Willder (2014)
10.2478/v10163-012-0005-9
The Value of Magnetic Resonance in Differentiation between Brain Glioma and Treatment Induced Injury
Anvita Bieza (2012)
10.11648/J.CRJ.20160403.11
Correlation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia
Syarif Ibrahim (2016)
10.2214/AJR.13.11109
Smaller reduction in 3D breast density associated with subsequent cancer recurrence in patients with breast cancer receiving adjuvant tamoxifen therapy.
J. Y. Kim (2014)
10.1186/1471-2407-12-257
SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?
Maria Tengström (2011)
10.1093/annonc/mdr448
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
K. Zaman (2012)
10.1093/annonc/mdr261
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.
M. Campone (2012)
10.1007/s12282-012-0437-z
GeneSearch™ BLN Assay could replace frozen section and touch imprint cytology for intra-operative assessment of breast sentinel lymph nodes
Yong-sheng Wang (2013)
10.1007/s10549-015-3322-6
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients
Chiya Oshiro (2015)
The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting.
H. Peiris (2017)
10.3892/ijo.2017.4057
Nestin-positive microvessel density is an independent prognostic factor in breast cancer.
Aleksandra Nowak (2017)
10.1093/jjco/hyp195
Clinical utility of the 70-gene MammaPrint profile in a Japanese population.
M. Ishitobi (2010)
Tratamiento adyuvante en cáncer de mama
A. L. Hernández (2012)
10.1093/annonc/mds118
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report.
P. Karlsson (2012)
10.1007/s00428-010-1033-2
Incomplete inside-out growth pattern in invasive breast carcinoma: association with lymph vessel invasion and recurrence-free survival
S. Kuba (2010)
10.4048/jbc.2012.15.4.401
Analysis of the Potent Prognostic Factors in Luminal-Type Breast Cancer
H. Kim (2012)
10.1038/bjc.2013.465
Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes
S. Kim (2013)
10.18231/J.IJPO.2019.040
Association of Ki67 expression with clinicopathological parameters and molecular classification in invasive breast carcinomas association of Ki67 expression with clinicopathological parameters and molecular
Sushma S Nigudgi (2019)
10.1186/s12885-016-2972-z
Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: a machine learning approach
F. Lin (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar